Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07217171 · ClinicalTrials.gov registry record · Phase 1
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell Carcinomas
A Phase 1 study of Bladder Cancer and Esophageal Squamous Cell Carcinoma, sponsored by EvolveImmune United.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 160
- Enrollment target
- 8
- Study locations
NCT07217171 is a Phase 1 study of Bladder Cancer and Esophageal Squamous Cell Carcinoma that is actively recruiting participants, run by EvolveImmune United. The registered enrollment target is 160 participants, below the 12,753-participant average among 175 other Bladder Cancer trials with a reported enrollment target (99% lower). The trial reports 8 study locations across 8 states.
The verdict
NCT07217171, a Phase 1 study of Bladder Cancer and Esophageal Squamous Cell Carcinoma, is actively recruiting participants, sponsored by EvolveImmune United.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 160 participants
- Enrollment target
- 8
- Study locations
Study Summary
The goal of this study is to evaluate the safety and effectiveness of EVOLVE104 in participants with advanced urothelial and squamous cell carcinomas who have previously taken standard treatment options, have declined or have been ineligible for treatment with these medications. Participants with advanced or metastatic cancer who meet all eligibility criteria may be eligible to participate in the study.
Conditions Studied
Interventions
- DRUG EVOLVE104
Study Locations (8)
California
- USC/Norris Comprehensive Cancer Center - Los Angeles
Connecticut
- Yale University Cancer Center - New Haven
Georgia
- The Winship Cancer Institute Emory University - Atlanta
Michigan
- START Midwest - Grand Rapids
New York
- Memorial Sloan Kettering Cancer Center - New York
Pennsylvania
- Thomas Jefferson University, Sidney Kimmel Cancer Center - Philadelphia
Tennessee
- SCRI - Nashville
Virginia
- Virginia Cancer Specialists - Fairfax
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 160 participants |
| Start Date | 2025-11-13 |
| Est. Completion | 2031-01-29 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07217171
The ClinicalTrials.gov registry entry for NCT07217171 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 160 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 12,753-participant average among 175 other Bladder Cancer trials with a reported enrollment target (99% lower). The listed sponsor is EvolveImmune United, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 10 conditions, with Bladder Cancer appearing as the primary indexed condition, and to 1 intervention - of which EVOLVE104 is the first listed.
NCT07217171 reports 8 study locations spanning 8 distinct geographic areas - top geographies include California, Connecticut, Georgia.
Frequently Asked Questions
What is clinical trial NCT07217171 about?
NCT07217171 is a clinical study titled "A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell Carcinomas". The goal of this study is to evaluate the safety and effectiveness of EVOLVE104 in participants with advanced urothelial and squamous cell carcinomas who have previously taken standard treatment options, have declined or have been ineligible for treatment with these medications. Participants with ad...
What is the current status of trial NCT07217171?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 160 participants. The study started on 2025-11-13. Estimated completion is 2031-01-29.
What conditions does trial NCT07217171 study?
This clinical trial studies the following conditions: Bladder Cancer, Esophageal Squamous Cell Carcinoma, Cervical Squamous Cell Carcinoma, Anal Squamous Cell Carcinoma, Cutaneous Squamous Cell Cancer.
What interventions are being tested in trial NCT07217171?
The interventions under investigation include: EVOLVE104 (DRUG).
Who is sponsoring clinical trial NCT07217171?
This trial is sponsored by EvolveImmune United, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07217171 being conducted?
This trial has 8 study locations across California, Connecticut, Georgia, Michigan, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Bladder Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.
RECRUITING · Phase 1
-
KEYMAKER-U04 Substudy 04D: A Clinical Study of New Treatments Given With Enfortumab Vedotin and Pembrolizumab in People With Urothelial Cancer (MK-3475-04D/KEYMAKER-U04)
RECRUITING · Phase 1
-
A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study of MGC026 in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
Sacituzumab Govitecan Plus EV in Metastatic UC
RECRUITING · Phase 1
-
Enfortumab Vedotin and Stereotactic Radiation for Localized, Cisplatin Ineligible Muscle Invasive Bladder Cancer
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.